Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
Status:
Completed
Trial end date:
2017-10-30
Target enrollment:
Participant gender:
Summary
This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine
extended-release oral suspension, CII) for the treatment of symptoms of
attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years.